©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Sep 14, 2013; 19(34): 5615-5621
Published online Sep 14, 2013. doi: 10.3748/wjg.v19.i34.5615
Published online Sep 14, 2013. doi: 10.3748/wjg.v19.i34.5615
Table 1 Current screening methods and guidelines for colorectal cancer
| Method | Sensitivity | Interval | Society |
| Fecal tests | |||
| FOBT | Yearly | USPSTF, ASGE, | |
| USMSTF | |||
| FIT | 65.8%[32,33] | Yearly | |
| Fecal DNA | 50%-60%[34] | Unspecified | USMSTF |
| Serum markers | |||
| CEA | 30%[35] | ||
| CA19-9 | |||
| Imaging tests | |||
| DCBE | 85%-97%[36] | Every 5 years | USMSTF |
| CTC | 55%-94%[37] | Every 5 years | USMSTF |
| Optical tests | |||
| FS | Every 5 years | USPSTF, ASGE, USMSTF | |
| Every 10 years | |||
| FC | USPSTF, ASGE, USMSTF |
- Citation: Li T, Leong MH, Harms B, Kennedy G, Chen L. MicroRNA-21 as a potential colon and rectal cancer biomarker. World J Gastroenterol 2013; 19(34): 5615-5621
- URL: https://www.wjgnet.com/1007-9327/full/v19/i34/5615.htm
- DOI: https://dx.doi.org/10.3748/wjg.v19.i34.5615